title: Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma.
abstract: OBJECTIVE
  Neurofibromatosis is associated with overactivation of the RAS-MAPK pathway. MEK inhibitors have been shown to be an effective treatment modality in other malignancies.
  
  
  METHODS
  We present a 24-year-old male with treatment-refractory neurofibromatosis-associated glioblastoma, who experienced clinical and radiological benefit from the MEK inhibitor, trametinib.
  
  
  CONCLUSIONS
  This case highlights the therapeutic success of a MEK inhibitor in neurofibromatosis-associated glioblastoma. As a corollary, this should prompt evaluation of MEK inhibitors in tumours associated with neurofibromatosis. It remains to be elucidated if tumours with somatic NF1 mutations may also benefit from therapy targeting the RAS-MAPK pathway.
authors.affiliation: Department of Medical Oncology, Austin Health, Heidelberg, Vic, Australia.
authors.forename: M
authors.initials: M
authors.lastname: Ameratunga
authors.affiliation: Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia.|University of Melbourne, Parkville, Vic, Australia.|St. Vincent's Hospital, University of Melbourne, Fitzroy, Vic, Australia.
authors.forename: G
authors.initials: G
authors.lastname: McArthur
authors.affiliation: Department of Medical Oncology, Austin Health, Heidelberg, Vic, Australia.
authors.forename: H
authors.initials: H
authors.lastname: Gan
authors.affiliation: Department of Medical Oncology, Austin Health, Heidelberg, Vic, Australia.
authors.forename: L
authors.initials: L
authors.lastname: Cher
keywords: medication; pharmacogenetics